Delaying surgery beyond six weeks after systemic therapy reduces postoperative morbidity without evidence of impaired oncologic outcomes in colorectal liver metastases - Takeaways - MDSpire

Delaying surgery beyond six weeks after systemic therapy reduces postoperative morbidity without evidence of impaired oncologic outcomes in colorectal liver metastases

  • By

  • Esther Giehl-Brown

  • Rajan Nikbakhsh

  • Ana Mansourkiaei

  • Laila Jötten

  • Bruno Christian Köhler

  • Thomas Longerich

  • Bo Kong

  • Arianeb Mehrabi

  • Markus W Büchler

  • Mohammed Al-Saeedi

  • Christoph Kahlert

  • June 30, 2026

  • 0 min

Share

  • 1

    Colorectal liver metastases (CRLM) occur in up to 20% of colorectal cancer patients at diagnosis, with surgical resection being the only curative option.

  • 2

    Neoadjuvant systemic therapy (NAT) can downstage initially unresectable CRLM, but its role in resectable cases remains controversial.

  • 3

    Optimal timing of surgery after NAT, known as time-to-surgery (TTS), may influence postoperative morbidity and long-term outcomes.

  • 4

    A retrospective analysis of 159 patients evaluated the impact of TTS on postoperative complications and oncological outcomes after surgery for CRLM.

  • 5

    The study aims to clarify the relationship between surgical timing and postoperative morbidity to inform perioperative decision-making.

Original Source(s)

Delaying surgery beyond six weeks after systemic therapy reduces postoperative morbidity without evidence of impaired oncologic outcomes in colorectal liver metastases

  • by Esther Giehl-Brown, Rajan Nikbakhsh, Ana Mansourkiaei, Laila Jötten, Bruno Christian Köhler, Thomas Longerich, Bo Kong, Arianeb Mehrabi, Markus W Büchler, Mohammed Al-Saeedi, Christoph Kahlert

  • June 30, 2026

Related Content

Integrated single-cell and spatial transcriptomics reveal immune landscape and NKT–Th1 signatures in colorectal cancer

Plasticity and antigen presentation by group 3 innate lymphoid cells in colorectal cancer

Integrative single-cell and bulk transcriptomic analyses identify DRAM1 as a candidate gene from fibroblast-associated transcriptional programs in colorectal cancer